Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) (CIK 0001290877) (CUVL)
Activity window: Oct. 25, 2025 to Oct. 24, 2026
Export this company’s current score, component values, matched signals, and scoring date as a one-row CSV snapshot.
The total combines correspondence volume, AI sentiment, matched keywords and signals, and a weighted 8-K adjustment, capped at 10.0. This is the 365-day v1 snapshot. Computed: Oct. 24, 2026. Latest filing activity: Jul. 15, 2026. These dates describe different events.
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Jul. 15, 2026 | CORRESP | Neutral/Informational | Moderate | Clinuvel Pharmaceuticals Limited has submitted a request to the U.S. Securities and Exchange Commission to expedite the effectiveness of their Registration Statement on Form 20-F.… | Read Filing EDGAR |
| Jul. 9, 2026 | CORRESP | Neutral/Informational | Low | Clinuvel Pharmaceuticals Limited has formally withdrawn its request for the acceleration of the effective date of its Registration Statement on Form 20-F, which was initially requ… | Read Filing EDGAR |
| Jul. 6, 2026 | CORRESP | Neutral/Informational | Moderate | Clinuvel Pharmaceuticals Ltd has submitted a request to the SEC to expedite the effectiveness of their Registration Statement on Form 20-F, aiming for it to become effective by Ju… | Read Filing EDGAR |
| Jun. 15, 2026 | CORRESP | Concern from SEC | Moderate | Clinuvel Pharmaceuticals Ltd has submitted a response to the SEC regarding comments on their Draft Registration Statement on Form 20-F. The SEC staff highlighted the need for the … | Read Filing EDGAR |
| Apr. 23, 2026 | UPLOAD | Concern from SEC | High | The SEC has reviewed Clinuvel Pharmaceuticals Limited's amended draft registration statement and has issued a comment regarding the financial statements included. They require tha… | Read Filing EDGAR |
| Apr. 7, 2026 | UPLOAD | Concern from SEC | High | The SEC has reviewed Clinuvel Pharmaceuticals Limited's amended draft registration statement and has provided several comments that require clarification and additional informatio… | Read Filing EDGAR |
| Mar. 19, 2026 | UPLOAD | Concern from SEC | High | The SEC has reviewed Clinuvel Pharmaceuticals Limited's Amendment No. 1 to Draft Registrant Statement on Form 20-F and has issued several comments requiring clarification and addi… | Read Filing EDGAR |
| Jan. 30, 2026 | UPLOAD | Concern from SEC | High | The SEC has reviewed Clinuvel Pharmaceuticals Limited's draft registration statement and has issued several comments requiring clarification and additional information. Key areas … | Read Filing EDGAR |